Ganesh Meera Bhanu, Xu Perry, Dean Nicholas, Tsai Kyle, Michael Jamie, McDonald Alyssa, Coskey Devyn Taylor, Khondakar Nabila, Fadl-Alla Allaa, Krambeck Amy Elizabeth
Northwestern University Feinberg School of Medicine, 420 E Superior Street, Chicago, IL 60611, USA.
Department of Urology, Northwestern University, Chicago, IL, USA.
Ther Adv Urol. 2025 May 17;17:17562872251338430. doi: 10.1177/17562872251338430. eCollection 2025 Jan-Dec.
Prostatitis can be challenging to treat. In refractory cases, prostatitis can be treated surgically with transurethral resection.
To examine the safety and efficacy of holmium laser enucleation of the prostate (HoLEP) as treatment in patients with prostatitis.
Patients who underwent HoLEP at a single center between January 2021 and August 2023 were retrospectively reviewed. Preoperative, intraoperative, and postoperative parameters were collected and analyzed. Patients with an ICD-10 diagnosis of prostatitis were identified and contacted postoperatively to evaluate for recurrent symptoms. Statistical significance was defined as < 0.05.
We identified 918 patients, of whom 26 (2.8%) had a diagnosis of prostatitis. There were no differences in baseline characteristics between patients with and without prostatitis. Patients with prostatitis were less likely to have a history of a neurologic disorder ( = 0.035), less likely to be catheter-dependent ( = 0.005), and less likely to have a preoperative positive urine culture ( = 0.040). There were no significant differences in intraoperative and postoperative parameters between the two groups. There were 23/26 (88.5%) patients with follow-up. There were no episodes of recurrent prostatitis and one episode of UTI after surgery, with a mean follow-up of 19.39 months (range: 7.45-30.19, SD: 7.38).
Prostatitis patients undergoing HoLEP had comparable safety and efficacy profiles to those who did not have prostatitis. On follow-up, 100% of patients with prostatitis did not experience recurrent prostatitis, suggesting that HoLEP may have a role in the management of prostatitis in the presence of benign prostatic enlargement.
前列腺炎治疗具有挑战性。在难治性病例中，前列腺炎可通过经尿道切除术进行手术治疗。
探讨钬激光前列腺剜除术（HoLEP）治疗前列腺炎患者的安全性和有效性。
对2021年1月至2023年8月在单一中心接受HoLEP手术的患者进行回顾性研究。收集并分析术前、术中和术后参数。确定国际疾病分类第十版（ICD - 10）诊断为前列腺炎的患者，并在术后进行随访以评估复发症状。统计学显著性定义为P < 0.05。
我们共纳入918例患者，其中26例（2.8%）诊断为前列腺炎。有前列腺炎和无前列腺炎的患者基线特征无差异。前列腺炎患者患神经疾病史的可能性较小（P = 0.035），依赖导尿管的可能性较小（P = 0.005），术前尿培养阳性的可能性较小（P = 0.040）。两组患者的术中和术后参数无显著差异。26例患者中有23例（88.5%）进行了随访。术后无复发性前列腺炎病例，有1例尿路感染，平均随访19.39个月（范围：7.45 - 30.19，标准差：7.38）。
接受HoLEP手术的前列腺炎患者与未患前列腺炎的患者具有相似的安全性和有效性。随访时发现前列腺炎患者均未出现复发性前列腺炎，这表明在存在良性前列腺增生的情况下，HoLEP可能在前列腺炎的治疗中发挥作用。
